ALK阳性非小细胞肺癌靶向治疗研究进展
摘要
随着分子医学研究进展及靶向药物的不断涌现，非小细胞肺癌（non—small cell lungcancer,NSCLC）的治疗已进入个体化诊疗时代。间变性淋巴瘤激酶（anaplastic lymphomakinase，ALK）基因重排是NSCLC中新的肿瘤驱动基因。针对ALK融合基因的小分子抑制剂克唑替尼（Crizotinib）是一种ATP竞争性酪氨酸酶抑制剂。
出处
《结核病与胸部肿瘤》
2015年第1期60-63,共4页
Tuberculosis and Thoracic Tumor
基金
本研究受北京市优秀人才培养项目（No.2013D003034000015）资助
参考文献28
-
1Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448(7153): 561-566.
-
2Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. Arch Pathol Lab Med, 2013, 137(6): 828-860.
-
3Choi YL, Soda M, Yamashita Y, et al. EMIA-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med, 2010, 363(18): 1734-1739.
-
4Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res, 2011, 71(18): 6051-6060.
-
5Chiarle R, Voana C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer, 2008, 8(1): 11-23.
-
6Solomon B, Wilner KD, Shaw AT. Current status of targeted therapy for anaplastie lymphoma kinase-rearranged non-small cell lung cancer. Clin Pharmaool Ther, 2013, 95(1): 15-23.
-
7Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK- positive lung cancer. Proc Natl Acad Sci, 2008, 105(50): 19893-19897.
-
8Sharma SV, Settleman J. Oneogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev, 2007, 21(24): 3214-3231.
-
9Rikova K, Gun A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oneogenie kinases in lung cancer. Cell, 2007, 131 (6): 1190-1203.
-
10Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res, 2013, 19(15): 4273- 4281.
-
1薛艳峰.肺癌间变性淋巴瘤激酶融合基因阳性患者四例的化学治疗和靶向治疗体会[J].实用医技杂志,2015,22(11):1204-1206.
-
2刘尧,闫晓红,杨乔,侯杰,周海平,王宝锋,耿熠.NSCLC患者EGFR-TKI靶向治疗的临床效果及预后分析[J].临床和实验医学杂志,2015,14(21):1771-1774. 被引量：6
-
3卞家蓉,徐兴祥.核因子-κB在非小细胞肺癌表皮生长因子受体-酪氨酸酶抑制剂耐药中的作用和机制[J].中华肺部疾病杂志（电子版）,2015,8(3):85-88.
-
4周春颜.伊马替尼的作用机制及临床应用[J].中外医疗,2011,30(28):121-122. 被引量：1
-
5蒋敏,钱晓萍,刘宝瑞.吉非替尼治疗非小细胞肺癌研究进展[J].现代肿瘤医学,2009,17(10):2026-2029. 被引量：14
-
6戈伟,闫亚飞.食管癌的分子靶向治疗进展[J].医学与哲学（B）,2016,37(10):14-16. 被引量：3
-
7赵会琴,蒲洁华.酪氨酸激酶抑制剂治疗胃肠道间质瘤的疗效观察[J].内蒙古中医药,2012,31(9):48-49.
-
8康小红,王立芳,王中奇,邓海滨,赵晓珍,徐振晔.肺岩宁方联合吉非替尼抑制肺癌裸鼠移植瘤细胞H1975生长及其作用机制[J].肿瘤防治研究,2014,41(1):1-4. 被引量：10
-
9魏旭东,李进东,刘宝兴,常玉喜,常栋.表皮生长因子受体基因在非小细胞肺癌中的突变情况及蛋白表达情况[J].中华临床医师杂志（电子版）,2014,8(4):15-18. 被引量：1
-
10蒋尧瀛,姜成威,王喆辉,张丽荣,王丽萍.甲状腺未分化癌5例临床病理特征分析[J].临床与实验病理学杂志,2016,32(11):1281-1283. 被引量：7
